The nonrandomized phase 2 APEC trial investigated first-line once-every-2-weeks cetuximab plus chemotherapy (investigator's choice of FOLFOX or FOLFIRI) studied patients with KRAS/RAS wild-type metastatic colorectal cancer. We observed an activity and safety profile similar to that reported in prior first-line pivotal studies involving weekly cetuximab, suggesting that once-every-2-weeks cetuximab is effective and tolerable as first-line therapy. Background: In patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC), outcomes with first-line chemotherapies are improved by adding weekly cetuximab. The APEC study investigated first-line once-every-2-weeks cetuximab plus chemotherapy for patients with KRAS wt mCRC; additional biomarker subgroups were also analyzed. Patients and Methods: APEC was a nonrandomized phase 2 trial conducted in the Asia-Pacific region. Patients (n ¼ 289) received once-every-2-weeks cetuximab with investigator's choice of chemotherapy (FOLFOX or FOLFIRI). The primary end point was best confirmed overall response rate (BORR); progression-free survival (PFS) and Ã Currently associated with Gleneagles Penang, Penang, Malaysia. ÃÃ Currently associated with Singapore Oncology Consultants. Clinical Colorectal Cancer June 2017 -e73 overall survival (OS) were secondary end points. Early tumor shrinkage (ETS) and depth of response (DpR) were also evaluated. Results: In the KRAS wt population, BORR was 58.8%, median PFS 11.1 months, and median OS 26.8 months. Expanded RAS mutational analysis revealed that patients with RAS wt mCRC had better outcomes (BORR ¼ 64.7%; median PFS ¼ 13.0 months; median OS ¼ 28.4 months). The data suggest that ETS and DpR may be associated with survival outcomes in the RAS wt population. Although this study was not designed to formally assess differences in outcome between treatment subgroups, efficacy results appeared similar for patients treated with FOLFOX and FOLFIRI. There were no new safety findings; in particular, grade 3/4 skin reactions were within clinical expectations. Conclusion: The observed activity and safety profile is similar to that reported in prior first-line pivotal studies involving weekly cetuximab, suggesting once-every-2-weeks cetuximab is effective and tolerable as first-line therapy and may represent an alternative to weekly administration.
Introduction
The antieepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab has been approved for the first-line treatment of patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) Cetuximab has a mean half-life of 112 hours, and pharmacokinetic data suggest similar steady-state bioavailability for the standard weekly schedule of cetuximab (250 mg/m 2 ) and a once-every-2-weeks dose of 500 mg/m 2 . 6 It is therefore plausible that cetuximab could be administered according to a once-every-2-weeks dosing schedule. Recent clinical evidence supports the activity and tolerability of such a regimen at a dose of 500 mg/m 2 .
7-10 Such a dosing schedule would potentially be more convenient to patients, particularly due to the 2-week dosing cycles utilized for FOLFOX and FOLFIRI. In light of these prior observations, a multicenter, nonrandomized phase 2 APEC study was conducted to assess the efficacy and safety of 500 mg/m 2 cetuximab once-every-2-weeks combined with FOLFOX or FOLFIRI as first-line treatment for patients with KRAS wt mCRC.
To reflect the outcome in the population for which cetuximab is currently approved, we also performed exploratory subgroup analyses based on expanded RAS mutational status (KRAS and NRAS exons 2-4). Further analyses considered BRAF and PIK3CA mutational testing, EGFR expression status, and the potential association between early tumor shrinkage (ETS) and depth of response (DpR) with survival outcomes. Because FOLFOX and FOLFIRI have shown similar efficacy in patients with mCRC, 11 including when used in combination with cetuximab, 12, 13 the study design included a nonrandomized allocation to either chemotherapy regimen, based on investigator's choice.
Patients and Methods

Study Design and Patients
APEC (NCT00778830) was a multicenter, nonrandomized, open-label phase 2 exploratory trial carried out in the Asia-Pacific region. APEC included adult patients (aged ! 18 years) from the Asia-Pacific region with KRAS wt metastatic adenocarcinoma of the colon or rectum. KRAS wt was defined as no detected mutations in KRAS exon 2 (codon 12/13). Eligible patients were required to have a life expectancy of ! 12 weeks, an Eastern Cooperative Oncology Group performance status of 0 or 1, presence of ! 1 bidimensionally measurable index lesion, and written informed consent. Patients were excluded if they had known or suspected brain metastasis and/or leptomeningeal disease; previous treatment with chemotherapy for colorectal cancer (excluding adjuvant therapy terminated > 6 months previously); or radiotherapy, surgery (excluding prior diagnostic biopsy), or any investigational drug in the 30 days before the start of treatment in this study.
All patients received cetuximab (500 mg/m 2 ) on the first day of every 14-day treatment cycle over 120 minutes for the first infusion, 90 minutes at the second infusion, and 60 minutes at the subsequent infusions. According to investigator's choice, patients received either FOLFOX (oxaliplatin 100 mg/m 2 , folinic acid (Figure 1 ). Treatment was planned to continue until the disease progressed, unacceptable toxicity was reported, or consent was withdrawn; when chemotherapy was discontinued, continuation of cetuximab as a maintenance regimen (until disease progression) was to be considered. After the end of study treatment, information on further anticancer treatment and survival was collected every 3 months.
Outcomes
Because all patients in the intention-to-treat (ITT) population received ! 1 dose of study treatment, efficacy analyses and safety assessments were conducted on the ITT population, which was defined as all patients with KRAS wt mCRC who received ! 1 dose of either study treatment (n ¼ 289). The primary end point was the best overall confirmed response rate (BORR); response to treatment was assessed every 8 weeks by radiologic imaging according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.0.
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Once-Every-2-Weeks Cetuximab Secondary end points were progression-free survival (PFS), overall survival (OS), and safety. In assessing the potential relationship of documented adverse events (AEs) to the study drugs (ie, cetuximab and/or chemotherapy), it was assumed that the AE was related to the study drugs unless the investigator definitively reported that the AE was unrelated to the study drugs.
The number of patients who underwent metastatic surgery, together with information on the localization of metastases removed and outcome of surgery with respect to residual tumor after surgery (R0, R1, R2, not evaluable), was evaluated in an exploratory analysis. In case of resection of > 1 metastasis, the worst outcome of surgery defined overall status.
All patients with an available tumor size evaluation at baseline and week 8 (n ¼ 269) were considered for an exploratory analysis of the potential association between ETS and survival outcomes (PFS and OS). ETS was categorized as ! 20% decrease in the sum of longest diameters of target lesions between baseline and posttreatment week 8.
A total of 159 patients with RAS wt mCRC were considered evaluable for an exploratory analysis of DpR, including its potential association with efficacy outcomes (PFS as well as OS). Evaluable patients were those who had quantitative tumor size assessments available from baseline and at least 1 postbaseline visit. DpR was defined as the extent of maximal tumor shrinkage (sum of tumor diameters at nadir divided by sum of tumor diameters at baseline) and was expressed as a percentage. Assessments were performed every 8 weeks by computed tomography or magnetic resonance imaging according to RECIST 1.0.
Expanded RAS Testing and Exploratory Biomarker Analysis
Expanded RAS (KRAS and NRAS exons 2-4; including retesting of KRAS exon 2) mutational status was assessed by Ion Torrent (Life Technologies, Thermo Fisher Scientific Life Sciences, Waltham, MA) next-generation sequencing (NGS). RAS wt was defined as no mutations in KRAS and NRAS exons 2-4; RAS mutant (mt) was defined as ! 1 mutation in exons 2-4 of KRAS and/or NRAS. Upon retesting via NGS, KRAS exon 2 mutations were detected in 10 patients from the KRAS wt ITT population, potentially owing to the higher sensitivity of NGS compared with the direct sequencing method initially used to screen patients for eligibility. These 10 patients were included, along with patients with KRAS exon 3-4 and NRAS exon 2-4 mutations, in the RAS mt population during the exploratory analysis. 
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Mutational status of BRAF and PIK3CA was assessed retrospectively by pyrosequencing. EGFR expression was assessed by immunohistochemistry using an EGFR pharmDx Kit (Dako, Glostrup, Denmark; Agilent Technologies, Santa Clara, CA) with a cutoff point of ! 5% of tumor cells exhibiting a staining intensity of ! 1þ for defining EGFR-detectable (< 5% was defined as EGFR-undectable).
Statistical Analysis
The primary analysis was planned to be performed in the ITT KRAS wt population. The study design did not plan for direct or statistical comparison between the FOLFOX and FOLFIRI treatment subgroups, as this comparison was not supported by randomization. The response rate from the overall population, as well as each treatment subgroup, and its 95% confidence interval (CI) was calculated using the Clopper-Pearson method. Estimates for the secondary efficacy variables PFS and OS were described applying the Kaplan-Meier method. All analyses were performed using SAS 9.1 or later software (SAS Institute, Cary, NC).
The sample size determination was not based on power considerations for a statistical test but on the confidence limit approach to ensure adequate precision of estimates. Based on the results from the CRYSTAL and OPUS studies, 1,2,4,5 a precision of estimates with 55% as the expected BORR in each of the 2 treatment subgroups was selected. A length of the 2-sided 95% CI (not exceeding 10 percentage points in each direction from the point estimate) was used as a reasonable precise estimate of the BORR for each of the 2 treatment subgroups if ! 96 patients received that specific combination treatment.
Results
Patient Populations
The first patient entered our study in February 2009, and the last patient's final treatment visit was in April 2014. In total, 289 Additional biomarker testing within the KRAS wt ITT population was conducted to assess the potential influences of mutations in RAS (KRAS and NRAS exons 2-4). Among the tumors from 203 evaluable patients, 167 (82.3%) were found to be RAS wt, defined as having no detectable mutations in exons 2-4 of KRAS and NRAS. The frequencies of BRAF and PIK3CA mutations were low (5.5% for BRAF; 3.5% and 1.0% for PIK3CA exons 9 and 20, respectively) (Supplemental Table 1 ; available in the online version). Due to the small number of patients with BRAF and PIK3CA mutations, the BRAF/PIK3CA mt groups were combined in our subsequent analyses.
Within the KRAS wt population, the baseline characteristics of the 2 treatment subgroups were generally well balanced. However, several exceptions existed, including the percentage of patients who were aged ! 65 years (22.9% FOLFOX and 30.7% FOLFIRI), baseline leukocyte count > 10,000/mm 3 (16.5% FOFOX and 7.9% FOLFIRI), and prior adjuvant therapy (21.3% FOLFOX and 46.5% FOLFIRI; previous oxaliplatin exposure in the adjuvant setting may have contributed to an increased frequency of investigator's choice of FOLFIRI in this study). Baseline characteristics of the RAS wt population were broadly similar to those of the KRAS wt population (Table 1) . Exposure to cetuximab and chemotherapy (irinotecan or oxaliplatin plus 5-FU), as measured by relative dose intensity, was similar between the 2 treatment subgroups (Supplemental Table 2 ; available in the online version). Furthermore, cetuximab relative dose intensity was ! 80% in the majority of patients in the KRAS wt, RAS wt, RAS mt, and RAS-evaluable populations (> 70% of patients in each population), with no major differences between the populations (data not shown). The median duration of cetuximab treatment was relatively long (z7.5 months; 32.1 weeks in the FOLFOX subgroup and 33.3 weeks in the FOLFIRI subgroup) and exceeded the median duration of chemotherapy administration (25.4 weeks for oxaliplatin; 32.0 weeks for irinotecan; and 27.8 weeks and 32.0 weeks for 5-FU in the FOLFOX and FOLFIRI subgroups, respectively), suggesting that investigators followed the recommendation to use cetuximab as maintenance therapy after withdrawal of chemotherapy (Supplemental Table 3 ; available in the online version).
Efficacy
Key efficacy measures for both the KRAS wt and RAS wt populations are summarized in Table 2 . The KRAS wt and RASevaluable populations were comparable.
In the KRAS wt population, BORR, the primary end point of the study, was 58.8% (95% CI, 52.9-64.6); further refinement of the most appropriate patient pool via expanded RAS analysis revealed a BORR of 64.7% (95% CI, 56.9-71.9) in the RAS wt population. Consistent with the relatively long median duration of treatment, median PFS was 11.1 months (95% CI, 9.3-11.8) and 13.0 months (95% CI, 11.1-14.8) in the KRAS wt and RAS wt populations, respectively. Median OS in the KRAS wt population was 26.8 Table 2 Efficacy in KRAS wt, RAS-Evaluable, RAS wt, and RAS mt Populations
BORR (95% CI), % 58. Figure 2 ). The survival rate in the KRAS wt population was 33% at 36 months and 23% at 48 months (36% and 26%, respectively, in the RAS wt population).
As anticipated, BORR, median PFS, and median OS were relatively low in patients with RAS mt mCRC, as compared with patients with RAS wt mCRC ( Table 2) .
The study was not designed to assess differences in outcomes based on treatment subgroup. However, as expected, efficacy results were similar for patients treated with FOLFOX versus FOLFIRI in both the KRAS wt and RAS wt populations (Table 2 and Figure 2) .
Postefirst-line anticancer treatment was received by 59.2% of the KRAS wt population. The most common postefirst-line treatment administered was chemotherapy (52.2%), and relatively few patients ( 20.8%) received postefirst-line biologics (Supplemental Table 4 ; available in the online version).
We also sought to address efficacy within a biomarker subpopulation defined by BRAF and PIK3CA mutational status. Among 203 evaluable patients, 175 were wt at both BRAF and PIK3CA, 15 with BRAF mt and PIK3CA wt, 12 were BRAF wt and PIK3CA mt, and 1 was BRAF mt and PIK3CA mt. BRAF/PIK3CA wt patients appeared to have numerically improved outcomes compared with patients with BRAF mt and/or PIK3CA mt tumors; however, definitive conclusions were precluded by the limited number of patients with BRAF/PIK3CA mutations in our study (Supplemental Table 5 ; available in the online version).
Additional biomarker efficacy subanalyses were conducted on the basis of EGFR expression. Among 154 evaluable patients, 124 had detectable EGFR expression versus 30 with undetectable Once-Every-2-Weeks Cetuximab
EGFR expression. There were no major differences in outcome between the EGFR subgroups, although caution is required when interpreting these analyses due to the small number of patients in some subgroups (Supplemental Table 6 ; available in the online version). During the study, 31 patients (10.7%) underwent surgery with curative intent (24 [12.8%] in the FOLFOX subgroup and 7 [6.9%] in the FOLFIRI subgroup). The R0 resection rate was 10.0% (29 of 289) in the KRAS wt population (22 [11.7%] in the FOLFOX subgroup and 7 [6.9%] in the FOLFIRI subgroup). Palliative surgery was undertaken in 5 additional patients (1 in the FOLFOX subgroup and 4 in the FOLFIRI subgroup). Thus, a total of 36 patients in the KRAS wt population underwent on-study surgery for metastases. The R0 resection rate was 10.8% (18 of 167) within the RAS wt population (15 [13.6%] in the FOLFOX subgroup and 3 [5.3%] in the FOLFIRI subgroup), and a total of 23 patients (13.8%) underwent on-study surgery for metastases.
Assessment for ETS was evaluable in 269 and 159 patients in the KRAS wt and RAS wt populations, respectively. Overall, 76.2% (205 of 269) of the evaluable patients with KRAS wt mCRC achieved ETS, whereas ETS occurred in 81.8% (130 of 159) of evaluable patients with RAS wt mCRC. In patients with KRAS wt and RAS wt mCRC, ETS was associated with longer PFS and OS; there were no major differences between the FOLFOX and FOL-FIRI subgroups (Table 3) .
The extent of tumor shrinkage was similar between the FOL-FOX and FOLFIRI treatment subgroups; among patients whose disease did not progress, tumor size continued to decrease as the duration of treatment increased (Supplemental Figure 1 ; available in the online version). 159 patients with RAS-wt mCRC were evaluable for DpR: median DpR was 62.2% (interquartile range [IQR], 39.1-80.0) within the overall DpR-evaluable population; within the FOLFOX (n ¼ 103) and FOLFIRI (n ¼ 56) treatment subgroups, median DpR was 62.2% (IQR, 40.0-80.7) and 62.5% (IQR, 38.1-79.0), respectively. The median time to tumor size nadir was 5.9 months (95% CI, 5.6-7.6) within the overall DpRevaluable population; median time to nadir was 5.9 months (95% CI, 5.6-7.6) and 7.4 months (95% CI, 5.1-9.2) within the FOLFOX and FOLFIRI treatment subgroups, respectively. Notably, there appeared to be an association between the extent of DpR and time to tumor size nadir: patients experiencing a deeper response seemed to achieve maximal tumor shrinkage later than Once-Every-2-Weeks Cetuximab
patients with a less deep response (Supplemental Figure 2 ; available in the online version). Furthermore, the data suggest that there was a relationship between the extent of DpR and PFS/OS (Supplemental Figure 3 ; available in the online version).
Safety
Neutropenia was the most common grade 3/4 AE in both treatment subgroups of the KRAS wt population. Grade 3/4 infusion-related reactions occurred in 4.8% of patients receiving cetuximab plus FOLFOX and in none of those receiving cetuximab plus FOLFIRI. Grade 3/4 acne-like rash occurred in 18.6% and 10.9% of patients receiving cetuximab in combination with FOL-FOX and FOLFIRI, respectively (Table 4) .
Serious AEs (SAEs) were experienced by 34.0% of patients treated with FOLFOX plus cetuximab and 36.6% of patients receiving FOLFIRI plus cetuximab in the KRAS wt population; pyrexia (3.7%) was the most common SAE among patients in the FOLFOX treatment subgroup, whereas intestinal obstruction (5.0%) was the most frequent SAE in the FOLFIRI treatment subgroup; the only other SAEs that occurred with ! 3% incidence in either treatment subgroup of the KRAS wt population were febrile neutropenia and diarrhea in the FOLFOX subgroup and neutropenia, diarrhea, pyrexia, hypokalemia, and deep vein thrombosis in the FOLFIRI subgroup. Within the KRAS wt population, 11.7% and 16.8% of patients in the FOLFOX and FOLFIRI subgroups experienced AEs leading to the permanent discontinuation of cetuximab, respectively. Skin and subcutaneous tissue disorders were responsible for permanent discontinuation of cetuximab in 2.7% and 3.0% of patients in the FOLFOX and FOLFIRI treatment subgroups, respectively. Oxaliplatin was permanently discontinued before confirmation of progressive disease in 33.5% of patients receiving FOLFOX, while irinotecan was permanently discontinued in 15.8% of patients receiving FOLFIRI. There were 4 deaths reported in the study; 2 of them were categorized as due to disease complication with no evidence of progression, the third one (interstitial pneumonitis) as being reasonably related to cetuximab plus FOLFOX combination as assessed by the investigator, and the last one as treatment related due to unexplained death with missing relationship.
The safety profile of cetuximab plus chemotherapy in both RAS wt treatment subgroups was comparable with that described above for the KRAS wt population. No new safety findings were identified (Table 4) .
Discussion
The APEC study has shown that once-every-2-weeks cetuximab with either FOLFOX or FOLFIRI is effective as a first-line therapy for mCRC in this Asia-Pacific study population. The observed median OS for the KRAS wt and RAS wt populations is similar to those reported in prior first-line pivotal studies involving weekly cetuximab plus FOLFOX or FOLFIRI that enrolled mainly white patients. 2, 5, [14] [15] [16] Cetuximab compliance in the APEC study was high, and the overall occurrence of AEs, including grade 3/4 acneiform skin reactions, was similar to historical rates for the weekly administration schedule of cetuximab plus chemotherapy and chemotherapy alone. 2, 5 Notably, the CECOG CORE 1.2.002 study has shown that the efficacy and safety of cetuximab in combination with FOLFOX4 is similar when administered weekly versus once every 2 weeks in patients with KRAS wt mCRC. 7, 14 These observations are further substantiated by data from the OPTIMIX and NORDIC 7.5 studies demonstrating the efficacy and tolerability of a once-every-2-weeks cetuximab regimen. 8, 9 Accordingly, once-every-2-weeks cetuximab may represent an alternative to weekly administration. Although this was not a randomized study and no formal statistical hypotheses were planned to be evaluated between treatment subgroups, as expected, the data suggest that cetuximab can be effectively combined with either chemotherapy regimen (FOLFOX or FOLFIRI). These findings are consistent with the CRYSTAL, OPUS, FIRE-3, and CALGB 80405 trials. 2, 5, [15] [16] [17] Furthermore, the safety profile within both treatment subgroups of the KRAS wt and RAS wt populations was comparable, and no new safety findings were identified. Rates of mutation in RAS (KRAS/NRAS exons 2-4), BRAF, and PIK3CA were consistent with those of previous studies, 2, 5, 18 suggesting that the mutation frequencies of these genes appear to be similar between Asians and whites. In accordance with our expectations, BORR, median PFS, and median OS were relatively low in patients with RAS mt mCRC, as compared with patients with RAS wt mCRC. Furthermore, relative to the KRAS wt population, the efficacy of cetuximab was numerically improved in the RAS wt population, demonstrating that expanded testing of RAS mutational status reveals a population of patients with better clinical outcomes. These results underline the importance of expanded RAS testing to select patients most likely to benefit from therapy with cetuximab. A prognostic role for BRAF and PIK3CA in mCRC has been suggested previously, although the potential predictive value of these 2 biomarkers remains controversial. 19, 20 In our study, there appeared to be a trend toward improved outcomes in the BRAF/ PIK3CA wt population compared with the mt populations; however, further studies with larger numbers of patients with BRAF/ PIK3CA mt tumors are needed to provide a conclusive result. Prior studies have indicated that patients with EGFRundetectable mCRC can respond to cetuximab. 21, 22 Although the relatively small number of patients in certain subgroups is a limitation of the present study, our results appear to be broadly consistent with these previous observations. Although the number of patients in certain subgroups of our study was relatively small, our results suggest that patients with ETS or high DpR may have derived increased benefit, in terms of PFS and OS, from cetuximab plus chemotherapy. These findings are similar to earlier subgroup analyses of analogous pivotal studies involving weekly cetuximab, as ETS has been correlated with improved long-term outcome in patients with KRAS/RAS wt mCRC treated with weekly cetuximab in the CRYSTAL and OPUS (at 8 weeks) as well as the FIRE-3 (at 6 weeks) trials 23, 24 ; similarly, extent of DpR has been associated with survival outcomes in CRYSTAL, OPUS, and FIRE-3. 24, 25 Our data further suggest that there are patients with RAS wt mCRC who may benefit from the continuation of treatment with cetuximab plus FOLFOX or FOLFIRI rather than treatment breaks (eg, upon ETS) to achieve maximal tumor reduction. Indeed, in our study, the median duration of cetuximab treatment was relatively
Ann-Lii Cheng et al
Clinical Colorectal Cancer June 2017 -e81 long (z7.5 months) and exceeded the median duration of chemotherapy administration (especially in the subgroup treated with FOLFOX and less pronounced in the FOLFIRI subgroup; Supplemental Table 3 ; available in the online version). The relatively long median PFS observed here (11.1 months in the KRAS wt population) is therefore noteworthy and consistent with the results of COIN-B, 26 suggesting that patients may derive benefit from the use of cetuximab as a maintenance regimen.
Conclusion
The present observations suggest that cetuximab plus FOLFOX or FOLFIRI in a once-every-2-week regimen is effective and tolerable as first-line therapy in this Asia-Pacific study population. Thus, once-every-2-weeks cetuximab may represent an alternative to weekly administration in patients with KRAS wt or RAS wt mCRC.
Clinical Practice Points
A chemotherapy doublet (either FOLFOX or FOLFIRI) plus weekly cetuximab represents standard-of-care first-line therapy for patients with KRAS/RAS wt mCRC. Indeed, the safety and efficacy of such a weekly regimen in patients with KRAS/RAS wt mCRC has been firmly established by the pivotal first-line CRYSTAL and OPUS studies. The present nonrandomized phase 2 trial investigated whether the well-tolerated beneficial treatment effect observed in patients with KRAS/RAS wt mCRC on adding weekly cetuximab to firstline chemotherapy persisted when the regimen was administered according to a once-every-2-weeks dosing schedule. Our findings suggest an activity and safety profile for 500 mg/m 2 cetuximab once every 2 weeks plus chemotherapy is similar to that reported in prior first-line pivotal studies involving weekly administration of 250 mg/m 2 after an initial dose of 400 mg/m 2 .
Accordingly-consistent with observations from the CECOG CORE 1.2.002, NORDIC 7.5, and OPTIMIX trials-the impact of the present study on future clinical practice is empirical validation of the effectiveness and tolerability of once-every-2-weeks cetuximab plus first-line chemotherapy in patients with KRAS/ RAS wt mCRC, suggesting that a once-every-2-weeks dosing schedule may represent an alternative to weekly administration. Our study further establishes that cetuximab can be effectively combined with either FOLFOX or FOLFIRI, a finding that is supported by data from the CRYSTAL, OPUS, FIRE-3, and CALGB 80405 trials.
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